| Literature DB >> 35012284 |
Hye-Mi Jang1, Mi Yeong Hwang1, Bong-Jo Kim1, Young Jin Kim1.
Abstract
Genome-wide association studies (GWASs) facilitated the discovery of countless disease-associated variants. However, GWASs have mostly been conducted in European ancestry samples. Recent studies have reported that these European-based association results may reduce disease prediction accuracy when applied in non-Europeans. Therefore, previously reported variants should be validated in non-European populations to establish reliable scientific evidence for precision medicine. In this study, we validated known associations with type 2 diabetes (T2D) and related metabolic traits in 125,850 samples from a Korean population genotyped by the Korea Biobank Array (KBA). At the end of December 2020, there were 8,823 variants associated with glycemic traits, lipids, liver enzymes, and T2D in the GWAS catalog. Considering the availability of imputed datasets in the KBA genome data, publicly available East-Asian T2D summary statistics, and the linkage disequilibrium among the variants (r2 < 0.2), 2,900 independent variants were selected for further analysis. Among these, 1,837 variants (63.3%) were statistically significant (p ≤ 0.05). Most of the non-replicated variants (n = 1,063) showed insufficient statistical power and decreased minor allele frequencies compared with the replicated variants. Moreover, most of known variants showed <10% genetic heritability. These results could provide valuable scientific evidence for future study designs, the current power of GWASs, and future applications in precision medicine in the Korean population.Entities:
Keywords: genome-wide association study; heritability; metabolic traits; single nucleotide polymorphism; type 2 diabetes
Year: 2021 PMID: 35012284 PMCID: PMC8752982 DOI: 10.5808/gi.21071
Source DB: PubMed Journal: Genomics Inform ISSN: 1598-866X
Fig. 1.Schematic representation of analysis flow. GWAS, genome-wide association study; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; TC, total cholesterol; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; T2D, type 2 diabetes; MAF, minor allele frequency; LD, linkage disequilibrium.
Summary of replication results
| Category | No. of variants | Replicated | Not replicated (p > 0.05) | |
|---|---|---|---|---|
| (p ≤ 0.05) | Total | % | ||
| Liver enzymes | ||||
| ALT | 35 | 22 | 13 | 62.9 |
| AST | 29 | 23 | 6 | 79.3 |
| GGT | 64 | 53 | 11 | 82.8 |
| Lipid traits | ||||
| HDL | 662 | 383 | 279 | 57.9 |
| LDL | 484 | 286 | 198 | 59.1 |
| TG | 566 | 294 | 272 | 51.9 |
| TC | 297 | 234 | 63 | 78.8 |
| Glycemic traits | ||||
| FPG | 80 | 53 | 27 | 66.3 |
| HbA1c | 71 | 60 | 11 | 84.5 |
| T2D | 612 | 429 | 183 | 70.1 |
| Total | 2,900 | 1,837 | 1,063 | 63.3 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; TC, total cholesterol; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; T2D, type 2 diabetes.
Estimated statistical power of non-replicated variants
| Category | No. of non-replicated variants | Statistical power | % (power > 80%) | |
|---|---|---|---|---|
| Min | Max | |||
| Liver enzymes | ||||
| ALT | 13 | 0.0501 | 0.4714 | 0 |
| AST | 6 | 0.0543 | 0.5133 | 0 |
| GGT | 11 | 0.0533 | 0.4250 | 0 |
| Lipid traits | ||||
| HDL | 279 | 0.0500 | 0.5325 | 0 |
| LDL | 198 | 0.0500 | 0.3633 | 0 |
| TG | 272 | 0.0500 | 0.6796 | 0 |
| TC | 63 | 0.0503 | 0.5133 | 0 |
| Glycemic traits | ||||
| FPG | 27 | 0.0500 | 0.3633 | 0 |
| HbA1c | 11 | 0.0510 | 0.4877 | 0 |
| T2D | 183 | 0.0501 | 0.9994 | 45.36 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ -glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; TC, total cholesterol; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; T2D, type 2 diabetes.
Fig. 2.Effect sizes and minor allele frequency of variants associated with glycemic traits and type 2 diabetes. The X-axis represents the minor allele frequency of the variants. The Y-axis represents the absolute scale of effect sizes of variants. Each circle indicates a variant. Variants were colored in blue if they were replicated in this study (p ≤ 0.05) and colored in red otherwise (p > 0.05). (A) Fasting plasma glucose (FPG). (B) Glycated hemoglobin (HbA1c). (C) Type 2 diabetes (T2D).
Estimated genetic heritability of known variants
| Category | No. of variants | Sample size | Estimated heritability (%) |
|---|---|---|---|
| Liver enzymes | |||
| ALT | 13 | 109,068 | 1.32 |
| AST | 6 | 109,230 | 1.32 |
| GGT | 11 | 102,729 | 6.62 |
| Lipid traits | |||
| HDL | 279 | 120,559 | 19.99 |
| LDL | 198 | 77,363 | 20.37 |
| TG | 272 | 120,377 | 14.03 |
| TC | 63 | 120,561 | 12.28 |
| Glycemic traits | |||
| FPG | 27 | 109,942 | 6.17 |
| HbA1c | 11 | 51,385 | 8.24 |
| T2D | 183 | 433,540 | 7.69 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ -glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; TC, total cholesterol; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; T2D, type 2 diabetes.